Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Syros Pharmaceuticals < Previous 1 2 Next > Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression June 13, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update May 14, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Participate in Upcoming Investor Conferences May 07, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 May 07, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression April 09, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update March 27, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial March 25, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 March 20, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Participate in TD Cowen 44th Annual Health Care Conference February 27, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene January 08, 2024 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants December 19, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine December 06, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Participate in Upcoming Investor Conferences November 21, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update November 14, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 November 07, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company October 02, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 07, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update August 08, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 04, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 August 01, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 05, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference June 08, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 01, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting May 25, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update May 10, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Present at JMP Securities 2023 Life Sciences Conference May 09, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 May 03, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update March 02, 2023 From Syros Pharmaceuticals Via Business Wire Tickers SYRS < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.